This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves
Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin
New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session
RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF
Preventing AF related strokes is vital. Protecting your brain protects your world.